Novo Nordisk aims to convince Europeans governments to pay for its obesity drug Wegovy for the most overweight or those with co-morbidities, its CEO said on Friday, emphasising both the medical ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy. 記事全文>>> Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial ...

Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

(Yicai) July 7 -- A public hospital in Beijing has issued the first prescription for Mazdutide, the first glucagon-like peptide-1 weight-loss drug developed by a Chinese firm and approved for ...